← Back to Clinical Trials
Recruiting NCT07229196

NCT07229196 Clinical Trial in Hypertensive Patients Comparing Two Cardiorespiratory Exercise Protocols, Low-volume Sprint Interval Training (SIT) Versus Moderate-intensity Continuous Training (MICT), to Evaluate Decreases in Ambulatory Blood Pressure and Other Clinical Variables.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07229196
Status Recruiting
Phase
Sponsor Unidad Enfermedades Cardiometabolicas- Hospital Interzonal General Agudos San Martin de La Plata
Condition Hypertension (HTN)
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2025-04-29
Primary Completion 2026-11

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 59 Years
Study Type INTERVENTIONAL
Interventions
SIT group: 2-4 maximal 20-30-second cycling sprints (≥100% VO₂max) with recovery intervals (2-4 min), total duration ≤15 minutes per session.MICT group: Continuous cycling at 50-70% of VO₂max, 15-30 minutes per session.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2025-04-29 with a primary completion date of 2026-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized clinical trial aims to compare two cardiorespiratory exercise training protocols - Sprint Interval Training (SIT), characterized by short, maximal-intensity efforts, versus Moderate-Intensity Continuous Training (MICT) - in patients with arterial hypertension. The primary objective is to evaluate the impact of both interventions on 24-hour ambulatory systolic blood pressure (ABPM) after a 12-week training period. Secondary outcomes include diastolic, daytime, and nighttime blood pressure, metabolic and hemodynamic parameters, body composition, and serum myokine levels (IL-6 and α-CGRP). Participants aged 30-59 years with diagnosed hypertension but without high cardiovascular risk will be recruited from the Cardio-Metabolic Disease Unit of Hospital San Martín (La Plata, Argentina). After a two-week familiarization period, eligible participants will be randomized to SIT or MICT groups. The intervention will last 12 weeks, with three supervised sessions per week. The study will provide valuable information about the effectiveness, safety, and clinical applicability of brief, high-intensity exercise for blood pressure control in hypertensive patients.

Eligibility Criteria

Inclusion Criteria: * Patients of both sexes between 30-59 years of age who meet the definition of hypertension. Hypertension will be defined as: 1. Those patients who report a history of hypertension and are under pharmacological treatment for it (Angiotensin Converting Enzyme Inhibitors/Angiotensin II Receptor Antagonists/Calcium Channel Blockers/Thiazide Diuretics/Beta Blockers) at the time of the evaluation. OR 2. Patients who report a history of hypertension during the evaluation and who, without pharmacological treatment, have average levels ≥140/90 mmHg will also be considered hypertensive. Exclusion Criteria: * Extreme body mass index (BMI) \<18.5 and ≥35. * Patients with office blood pressure readings ≥160/100 mmHg. * Patients with high cardiovascular risk conditions such as type II diabetes, chronic kidney disease (\<60 milliseconds), history of cerebrovascular disease, coronary artery disease, peripheral arterial disease, or heart failure (Framingham Criteria clinical diagnosis). * Pregnant or postpartum women up to 3 months old. * Patients with psychophysical limitations that make exercise difficult. * Patients with a history of active malignant neoplastic disease under treatment. Elimination Criteria -Patients whose pharmacological treatment is initiated or modified during the follow-up after 3 months.

Contact & Investigator

Central Contact

Julian Minetto, Physican

✉ jjminetto@hotmail.com

📞 +542214835429

Principal Investigator

Walter Espeche

PRINCIPAL INVESTIGATOR

Hospital Interzonal General San Martin

Frequently Asked Questions

Who can join the NCT07229196 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 59 Years, studying Hypertension (HTN). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07229196 currently recruiting?

Yes, NCT07229196 is actively recruiting participants. Contact the research team at jjminetto@hotmail.com for enrollment information.

Where is the NCT07229196 trial being conducted?

This trial is being conducted at La Plata, Argentina.

Who is sponsoring the NCT07229196 clinical trial?

NCT07229196 is sponsored by Unidad Enfermedades Cardiometabolicas- Hospital Interzonal General Agudos San Martin de La Plata. The principal investigator is Walter Espeche at Hospital Interzonal General San Martin. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology